Your browser doesn't support javascript.
loading
Detection of a SARS-CoV-2 variant of concern in South Africa.
Tegally, Houriiyah; Wilkinson, Eduan; Giovanetti, Marta; Iranzadeh, Arash; Fonseca, Vagner; Giandhari, Jennifer; Doolabh, Deelan; Pillay, Sureshnee; San, Emmanuel James; Msomi, Nokukhanya; Mlisana, Koleka; von Gottberg, Anne; Walaza, Sibongile; Allam, Mushal; Ismail, Arshad; Mohale, Thabo; Glass, Allison J; Engelbrecht, Susan; Van Zyl, Gert; Preiser, Wolfgang; Petruccione, Francesco; Sigal, Alex; Hardie, Diana; Marais, Gert; Hsiao, Nei-Yuan; Korsman, Stephen; Davies, Mary-Ann; Tyers, Lynn; Mudau, Innocent; York, Denis; Maslo, Caroline; Goedhals, Dominique; Abrahams, Shareef; Laguda-Akingba, Oluwakemi; Alisoltani-Dehkordi, Arghavan; Godzik, Adam; Wibmer, Constantinos Kurt; Sewell, Bryan Trevor; Lourenço, José; Alcantara, Luiz Carlos Junior; Kosakovsky Pond, Sergei L; Weaver, Steven; Martin, Darren; Lessells, Richard J; Bhiman, Jinal N; Williamson, Carolyn; de Oliveira, Tulio.
Afiliación
  • Tegally H; KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa.
  • Wilkinson E; KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa.
  • Giovanetti M; Laboratorio de Flavivirus, Fundacao Oswaldo Cruz, Rio de Janeiro, Brazil.
  • Iranzadeh A; Laboratório de Genética Celular e Molecular, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
  • Fonseca V; Computational Biology Division, Department of Integrative Biomedical Sciences, University of Cape Town, Cape Town, South Africa.
  • Giandhari J; KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa.
  • Doolabh D; Laboratório de Genética Celular e Molecular, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
  • Pillay S; KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa.
  • San EJ; Division of Medical Virology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
  • Msomi N; KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa.
  • Mlisana K; KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa.
  • von Gottberg A; Discipline of Virology, School of Laboratory Medicine and Medical Sciences and National Health Laboratory Service (NHLS), University of KwaZulu-Natal, Durban, South Africa.
  • Walaza S; NHLS, Johannesburg, South Africa.
  • Allam M; Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.
  • Ismail A; National Institute for Communicable Diseases, NHLS, Johannesburg, South Africa.
  • Mohale T; School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Glass AJ; National Institute for Communicable Diseases, NHLS, Johannesburg, South Africa.
  • Engelbrecht S; School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Van Zyl G; National Institute for Communicable Diseases, NHLS, Johannesburg, South Africa.
  • Preiser W; National Institute for Communicable Diseases, NHLS, Johannesburg, South Africa.
  • Petruccione F; National Institute for Communicable Diseases, NHLS, Johannesburg, South Africa.
  • Sigal A; School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Hardie D; Department of Molecular Pathology, Lancet Laboratories, Johannesburg, South Africa.
  • Marais G; Division of Medical Virology, Faculty of Medicine and Health Sciences, Stellenbosch University and NHLS Tygerberg Hospital, Cape Town, South Africa.
  • Hsiao NY; Division of Medical Virology, Faculty of Medicine and Health Sciences, Stellenbosch University and NHLS Tygerberg Hospital, Cape Town, South Africa.
  • Korsman S; Division of Medical Virology, Faculty of Medicine and Health Sciences, Stellenbosch University and NHLS Tygerberg Hospital, Cape Town, South Africa.
  • Davies MA; Centre for Quantum Technology, University of KwaZulu-Natal, Durban, South Africa.
  • Tyers L; National Institute for Theoretical Physics (NITheP), University of KwaZulu-Natal, Durban, South Africa.
  • Mudau I; Africa Health Research Institute, Durban, South Africa.
  • York D; School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa.
  • Maslo C; Max Planck Institute for Infection Biology, Berlin, Germany.
  • Goedhals D; Division of Medical Virology, NHLS Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa.
  • Abrahams S; Division of Medical Virology, NHLS Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa.
  • Laguda-Akingba O; Division of Medical Virology, NHLS Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa.
  • Alisoltani-Dehkordi A; Division of Medical Virology, NHLS Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa.
  • Godzik A; Centre for Infectious Disease Epidemiology and Research, University of Cape Town, Cape Town, South Africa.
  • Wibmer CK; Western Cape Government: Health, Cape Town, South Africa.
  • Sewell BT; Division of Medical Virology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
  • Lourenço J; Division of Medical Virology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
  • Alcantara LCJ; Molecular Diagnostics Services, Durban, South Africa.
  • Kosakovsky Pond SL; Department of Quality Leadership, Netcare Hospitals, Johannesburg, South Africa.
  • Weaver S; Division of Virology, NHLS Universitas Academic Laboratories, University of The Free State, Bloemfontein, South Africa.
  • Martin D; NHLS, Port Elizabeth, South Africa.
  • Lessells RJ; NHLS, Port Elizabeth, South Africa.
  • Bhiman JN; Department of Laboratory Medicine and Pathology, Faculty of Health Sciences, Walter Sisulu University, Mthatha, South Africa.
  • Williamson C; Division of Medical Virology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
  • de Oliveira T; Division of Biomedical Sciences, University of California Riverside School of Medicine, Riverside, CA, USA.
Nature ; 592(7854): 438-443, 2021 04.
Article en En | MEDLINE | ID: mdl-33690265
Continued uncontrolled transmission of SARS-CoV-2 in many parts of the world is creating conditions for substantial evolutionary changes to the virus1,2. Here we describe a newly arisen lineage of SARS-CoV-2 (designated 501Y.V2; also known as B.1.351 or 20H) that is defined by eight mutations in the spike protein, including three substitutions (K417N, E484K and N501Y) at residues in its receptor-binding domain that may have functional importance3-5. This lineage was identified in South Africa after the first wave of the epidemic in a severely affected metropolitan area (Nelson Mandela Bay) that is located on the coast of the Eastern Cape province. This lineage spread rapidly, and became dominant in Eastern Cape, Western Cape and KwaZulu-Natal provinces within weeks. Although the full import of the mutations is yet to be determined, the genomic data-which show rapid expansion and displacement of other lineages in several regions-suggest that this lineage is associated with a selection advantage that most plausibly results from increased transmissibility or immune escape6-8.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Filogenia / Filogeografía / SARS-CoV-2 / COVID-19 / Mutación Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Humans País/Región como asunto: Africa Idioma: En Revista: Nature Año: 2021 Tipo del documento: Article País de afiliación: Sudáfrica

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Filogenia / Filogeografía / SARS-CoV-2 / COVID-19 / Mutación Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Humans País/Región como asunto: Africa Idioma: En Revista: Nature Año: 2021 Tipo del documento: Article País de afiliación: Sudáfrica